Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.22 -0.11 (-0.32%)
Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
32 33 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug ↗
This story was first published on the Benzinga India portal. 
Via Benzinga
News headline image
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug ↗
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And Raise ↗
The company also raised the lower boundary of its guidance for full-year sales. 
Via Investor's Business Daily
News headline image
3 Bargain Stocks to Buy on the Dip ↗
These stocks should be poised to rebound. 
Via The Motley Fool
News headline image
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
S&P Slashes Ratings Of Five US Banks, SEC Fines Fintech Adviser Titan For Misleading Crypto Claims, Microsoft Modifies Activision Blizzard Purchase: Today's Top Stories ↗
Benzinga 
Via Benzinga
Topics Regulatory Compliance Stocks
News headline image
Big Pharma Price-Fixing: Teva and Glenmark's $255M Settlement Shines Light on Industry Issues ↗
Drugmaker Teva Pharmaceutical Industries Limited (NYSE: TEVA) has  
Via Benzinga
News headline image
Teva Settles Price Fixing Charges With U.S. DOJ
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning ↗
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated  
Via Benzinga
News headline image
Supreme Court Halts Purdue Pharma's $6B Settlement: Sackler Family's Shield From Opioid Lawsuits Challenged ↗
On Thursday, the Supreme Court temporarily blocked a $6-billion bankruptcy settlement by Purdue Pharma, the maker of the opioid OxyContin, that would shield the Sackler family from civil lawsuits... 
Via Benzinga
Topics Bankruptcy Lawsuit
News headline image
Teva Pharmaceutical, Marathon Oil And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed lower by over 1% on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract. 
Via Benzinga
News headline image
Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript ↗
TEVA earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Powell Industries, Inc. (NASDAQ: POWL) shares jumped... 
Via Benzinga
News headline image
Teva Pharma's Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo ↗
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q2 sales reached $3.88 billion, up 2% Y/Y (4% on constant currency), slightly beating the  
Via Benzinga
News headline image
Teva Reports Second Quarter 2023 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
News headline image
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 ↗
 
Via Benzinga
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva's Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit ↗
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.  
Via Benzinga
News headline image
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Geopolitical Risks Prevail ↗
A discussion about current geopolitical risks and their impact on commodity and stock markets. 
Via Talk Markets
News headline image
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity ↗
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients... 
Via Benzinga
News headline image
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.